Cytology versus HPV testing for cervical cancer screening in the general population

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 8, 2017, Pages

  Koliopoulos, George ^a   Nyaga, Victoria N ^b   Santesso, Nancy ^c   Bryant, Andrew ^d   Martin Hirsch, Pierre P L ^e   Mustafa, Reem A ^c   Schünemann, Holger ^c   Paraskevaidis, Evangelos ^f   Arbyn, Marc ^b  

^a HELENA VENIZELOU HOSPITAL   (Greece)

^b SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^c MCMASTER UNIVERSITY   (Canada)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e ROYAL PRESTON HOSPITAL   (United Kingdom)

^f UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

ADENOCARCINOMA IN SITU; APTIMA TEST; CANCER GRADING; CANCER SCREENING; CLINICAL STUDY; COLPOSCOPY; COMPARATIVE EFFECTIVENESS; CONVENTIONAL CYTOLOGY; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE E6; HUMAN PAPILLOMAVIRUS TYPE E7; INTERMETHOD COMPARISON; LIQUID BASED CYTOLOGY; NONHUMAN; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION; POPULATION; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; REVIEW; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; STANDARD; SYSTEMATIC REVIEW; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; EARLY CANCER DIAGNOSIS; FEMALE; META ANALYSIS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PRECANCEROUS CONDITIONS; PROCEDURES; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR; VIROLOGY;

ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PRECANCEROUS CONDITIONS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 85027383553     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008587.pub2     Document Type: Review

References (144)

1. Agorastos T, Dinas K, Lloveras B, de Sanjose S, Kornegay JR, Bonti H, et al. Human papillomavirus testing for primary screening in women at low risk of developing cervical cancer. The Greek experience. Gynecologic Oncology 2005;96:714-20. 5827742
2. Agorastos T, Chatzistamatiou K, Katsamagkas T, Koliopoulos G, Daponte A, Constantinidis T, et al. Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology. PLoS ONE 2015;10(3):e0119755. 5827744
3. Belinson JL, Qiao YL, Pretorius RG, Zhang WH, Rong SD, Huang MN, et al. Shanxi Province cervical cancer screening study II: self-sampling for high-risk human papillomavirus compared to direct sampling for human papillomavirus and liquid based cervical cytology. International Journal of Gynecological Cancer 2003;13:819-26. 5827746
4. Belinson SE, Wulan N, Li R, Zhang W, Rong X, Zhu Y, et al. SNIPER: a novel assay for human papillomavirus testing among women in Guizhou, China. International Journal of Gynecological Cancer 2010;20:1006-10. 5827748
5. Bigras G, de Marval F. The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13, 842 women. British Journal of Cancer 2005;93:575-81. 5827750
6. Blumenthal PD, Gaffikin L, Chirenje ZM, McGrath J, Womack S, Shah K. Adjunctive testing for cervical cancer in low resource settings with visual inspection, HPV, and the Pap smear. International Journal of Gynaecology and Obstetrics 2001;72:47-53. 5827752
7. Cardenas-Turanzas M, Nogueras-Gonzalez GM, Scheurer ME, Adler-Storthz K, Benedet JL, Beck R, et al. The performance of Human papillomavirus high-risk DNA testing in the screening and diagnostic settings. Cancer Epidemiology, Biomarkers & Prevention 2008;17:2865-71. 5827754
8. Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a sub analysis of the ATHENA study. Lancet Oncology 2011;12:880-90. 5827756
9. Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. British Journal of Cancer 2001;84:1616-23. 5827758
10. Cuzick J, Szarewski A, Terry G, Ho L, Hanby A, Maddox P, et al. Human papillomavirus testing in primary cervical screening. Lancet 1995;345:1533-6. 5827760
11. Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, et al. HPV testing in primary screening of older women. British Journal of Cancer 1999;81:554-8. 5827762
12. Cuzick J, Swarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. The Lancet 2003;362:1871-6. 5827764
13. de Cremoux P, Coste J, Sastre-Garau X, Thioux M, Bouillac C, Labbe S, et al. Efficiency of the hybrid capture 2 HPV DNA test in cervical cancer screening. American Journal of Clinical Pathology 2003;120:492-9. 5827766
14. Depuydt CE, Makar AP, Ruymbeke MJ, Benoy IH, Vereecken AJ, Bogers JJ. BD-ProExC as adjunct molecular marker for improved detection of CIN2+ after HPV primary screening. Cancer Epidemiol Biomarkers & Prevention 2011;20:628-37. 5827768
15. Ferreccio C, Barriga MI, Lagos M, Ibanez C, Poggi H, Gonzalez F, et al. Screening trial of human papillomavirus for early detection of cervical cancer in Santiago, Chile. International Journal of Cancer 2013;132:916-23. 5827770
16. Gravitt PE, Paul P, Katki HA, Vendantham H, Ramakrishna G, Sudula M, et al. Effectiveness of VIA, Pap and HPV DNA testing in a cervical cancer screening program in a peri-urban community in Andra Pradesh, India. PLOS one 2010;5:e13711. 5827772
17. Hovland S, Arbyn M, Lie AK, Ryd W, Borge B, Berle EJ, et al. A comprehensive evaluation of the accuracy of cervical pre-cancer detection methods in a high-risk area in East Congo. British Journal of Cancer 2010;102:957-65. 5827774
18. Iftner T, Becker S, Neis KJ, Castanon A, Iftner A, Holz B, et al. Head-to-head comparison of the RNA-based Aptima human papillomavirus (HPV) assay and the DNA-based hybrid capture 2 HPV test in a routine screening population of women aged 30 to 60 years in Germany. Journal of Clinical Microbiology 2015;53:2509-16. 5827776
19. Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002;288:1749-57. 5827778
20. Labani S, Asthana S, Sodhani P, Gupta S, Bhambhani S, Pooja B, et al. Care HPV cervical cancer screening demonstration in a rural population of North India. European Journal of Obstetrics & Gynecology and Reproductive Biology 2014;176:75-9. 5827780
21. Li N, Shi J-F, Franceshi S, Zhang W-H, Dai M, Liu B, et al. Different cervical cancer screening approaches in a Chinese multicentre study. British Journal of Cancer 2009;100:532-7. 5827782
22. Mahmud SM, Sangwa-Lugoma G, Nasr SH, Kayembe PK, Tozin RR, Drouin P, et al. Comparison of human papillomavirus testing and cytology for cervical cancer screening in a primary health care setting in the Democratic Republic of the Congo. Gynecologic Oncology 2012;124:286-91. 5827784
23. McAdam M, Sakita J, Tarivonda L, Pang J, Frazer IH. Evaluation of a cervical cancer screening program based on HPV testing and LLETZ excision in a low resource setting. PLoS ONE 2010;5:e13266. 5827786
24. McAdam M, Sakita J, Tarivonda L, Pang J, Frazer IH. Evaluation of a cervical cancer screening program based on HPV testing and LLETZ excision in a low resource setting. PLoS ONE 2010;5:e13266. 5827788
25. Monsonego J, Hudgens MG, Zerat L, Zerat J-C, Syrjanen K, Halfon P, et al. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening: the FASE study. International Journal of Cancer 2011;129:691-701. 5827790
26. Moy LM, Zhao F-H, Li L-Y, Ma J-F, Zhang Q-M, Chen F, et al. Human papillomavirus testing and cervical cytology in primary screening for cervical cancer among women in rural China: comparison of sensitivity, specificity, and frequency of referral. International Journal of Cancer 2010;127:646-56. 5827792
27. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. Journal of the National Cancer Institute 2009;101:88-99. 5827794
28. Nieves L, Enerson CL, Belinson S, Brainard J, Chiesa-Vottero A, Nagore N, et al. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection. International Journal of Gynecological Cancer 2013;23:513-8. 5827796
29. Pan Q, Belinson JL, Li L, Pretorius RG, Qiao YL, Zhang WH, et al. A thin layer, liquid-based Pap test for mass screening in an area of China with a high incidence of cervical carcinoma. A cross-sectional, comparative study. Acta Cytologica 2003;47:45-50. 5827798
30. Paraskevaidis E, Malamou-Mitsi V, Koliopoulos G, Pappa L, Lolis E, Georgiou I, et al. Expanded cytological referral criteria for colposcopy in cervical screening: comparison with human papillomavirus testing. Gynecologic Oncology 2001;82:355-9. 5827800
31. Petry KU, Menton S, Menton M, van Loenen-Frosch F, de Carvalho Gomes H, Holz B, et al. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. British Journal of Cancer 2003;88:1570-7. 5827802
32. Qiao YI, Sellors JW, Eder PS, Bao Y-P, Lim JM, Zhao F-H, et al. A new HPV DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncology 2008;9:929-36. 5827804
33. Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, et al. Human papillomavirus testing and liquid based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. Journal of the National Cancer Institute 2006;98:765-74. 5827806
34. Salmeron J, Lazcano-Ponce E, Lorincz A, Hernandez M, Hernandez P, Leyva A, et al. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico. Cancer Causes & Control 2003;14:505-12. 5827808
35. Sankaranarayanan R, Chatterji R, Shastri SS, Wesley RS, Basu P, Mahe C, et al. Accuracy of human papillomavirus testing in primary screening of cervical neoplasia: results from a multicenter study in India. International Journal of Cancer 2004;112:341-7. 5827810
36. Sarian LO, Derchain SF, Naud P, Roteli-Martins C, Longatto-Filho A, Tatti S, et al. Evaluation of visual inspection with acetic acid (VIA), Lugol's Iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS study. Journal of Medical Screening 2005;12:142-9. 5827812
37. Schneider A, Hoyer H, Lotz B, Leistritza S, Kuhne-Heid R, Nindl I, et al. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. International Journal of Cancer 2000;89:529-34. 5827814
38. Shipitsyna E, Zolotoverkhaya E, Kuevda D, Nasonova V, Romanyuk T, Khachaturyan A, et al. Prevalence of high-risk human papillomavirus types and cervical squamous intraepithelial lesions in women over 30 years of age in St. Petersburg, Russia. Cancer Epidemiology 2011;35:160-4. 5827816
39. Syrjaenen S, Shabalova I. Human papillomavirus testing and conventional Pap smear cytology as optional screening tools of women at different risks for cervical cancer in the countries of the former Soviet Union. Journal of Lower Genital Tract Disease 2002;6:97-110. 5827818
40. Wu R, Belinson SE, Du H, Na W, Qu X, Wu R, et al. Human papillomavirus messenger RNA assay for cervical cancer screening: the Shenzhen Cervical Cancer Screening Trial I. International Journal of Gynecological Cancer 2010;20:1411-4. 5827820
41. An HJ, Cho NH, Lee SY, Kim IH, Lee C, Mun MS, et al. Correlation of cervical carcinoma and precancerous lesions with human papillomavirus (HPV) genotypes detected with the HPV DNA Chip Microarray Method. Cancer 2003;97:1672-80. 5827822
42. Belinson J, Qiao YL, Pretorius R, Zhang WH, Elson P, Li L, et al. Shanxi province cervical cancer screening study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecologic Oncology 2001;83:439-44. 5827824
43. Belinson JL, Hu S, Niyazi M, Pretorius RG, Wang H, Wen C, et al. Prevalence of type-specific human papillomavirus in endocervical, upper and lower vaginal, perineal and vaginal self-collected specimens: implications for vaginal self-collection. International Journal of Cancer 2010;127:1151-7. 5827826
44. Belinson JL, Wu R, Belinson SE, Qu X, Yang B, Du H, et al. A population-based clinical trial comparing endocervical high-risk HPV testing using hybrid capture 2 and Cervista From the SHENCCAST II Study. American Journal of Clinical Pathology 2011;135:790-5. 5827828
45. Belinson JL, Du H, Yang B, Wu R, Belinson SE, Qu X, et al. Improved sensitivity of vaginal self-collection and high-risk human papillomavirus testing. International Journal of Cancer 2012;15:1855-60. 5827830
46. Benevolo M, Terrenato I, Mottolese M, Marandino F, Carosi M, Rollo F, et al. Diagnostic and prognostic validity of the human papillomavirus E6/E7 mRNA test in cervical cytological samples of HC2-positive patients. Cancer Causes & Control 2011;22:869-75. 5827832
47. Benevolo M, Vocaturo A, Caraceni D, French D, Rosini S, Zappacosta R, et al. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test. Journal of Clinical Microbiology 2011;49:2643-50. 5827834
48. Benoy IH, Vanden Broeck D, Ruymbeke MJ, Sahebali S, Arbyn M, Bogers JJ, et al. Prior knowledge of HPV status improves detection of CIN2+ by cytology screening. American Journal of Obstetrics and Gynecology 2011;205:569.e1-7. 5827836
49. Castle PE, Schiffman M, Wheeler CM, Wentzensen N, Gravitt PE. Impact of improved classification on the association of human papillomavirus with cervical precancer. American Journal of Epidemiology 2010;171:155-63. 5827838
50. Chao A, Chang C-J, Lai C-H, Chao F-Y, Hsu Y-H, Chou H-H, et al. Incidence and outcome of acquisition of human papillomavirus infection in women with normal cytology - a population-based cohort study from Taiwan. International Journal of Cancer 2010;126:191-8. 5827840
51. Coquillard G, Palao B, Patterson BK. Quantification of intracellular HPV E6/E7 mRNA expression increases the specificity and positive predictive value of cervical cancer screening compared to HPV DNA. Gynecologic Oncology 2011;120:89-93. 5827842
52. Costa S, Sideri M, Syrjanen K, Terzano P, De Nuzzo M, De Simone P, et al. Combined Pap smear, cervicography and HPV DNA testing in the detection of cervical intraepithelial neoplasia and cancer. Acta Cytologica 2000;44:310-18. 5827844
53. Coste J, Cochand-Priollet B, de Cremoux P, Le Galles C, Cartier I, Molinie V, et al. Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening. BMJ 2003;326:733-7. 5827846
54. Dai M, Bao YP, Li N, Clifford GM, Vaccarella S, Snijders PJ, et al. Human papillomavirus infection in Shanxi Province, People's Republic of China: a population-based study. British Journal of Cancer 2006;95:96-101. 5827848
55. de Andrade ACV, Luz PM, Velasque L, Veloso VG, Moreira RI, Russomano F, et al. Factors associated with colposcopy-histopathology confirmed cervical intraepithelial neoplasia among HIV infected women from Rio De Janeiro, Brazil. PLoS ONE 2011;6(3):e18297. 5827850
56. Denny L, Kuhn L, Pollack A, Wainwright H, Wright TC. Evaluation of alternative methods of cervical cancer screening for resource-poor settings. Cancer 2000;89:826-33. 5827852
57. Depuydt CE, Benoy IH, Beert JF, Criel AM, Bogers JJ, Arbyn M. Clinical validation of a type-specific real-time quantitative human papillomavirus PCR against the performance of hybrid capture 2 for the purpose of cervical cancer screening. Journal of Clinical Microbiology 2012;50:4073-7. 5827854
58. De Vuyst H, Claeys P, Njiru S, Muchiri L, Steyaert S, De Sutter P, et al. Comparison of Pap smear, visual inspection with acetic acid, human papillomavirus DNA-PCR testing and cervicography. International Journal of Gynecology and Obstetrics 2005;89:120-6. 5827856
59. Diamantopoulou S, Spathis A, Chranioti A, Anninos D, Stamataki M, Chrelias C, et al. Liquid based cytology and HPV DNA testing in a Greek population compared to colposcopy and histology. Clinical and Experimental Obstetrics & Gynecology 2013;40:131-6. 5827858
60. Ferreccio C, Bratti MC, Sherman ME, Herrero R, Wacholder S, Hildesheim A, et al. A comparison of single and combined visual, cytologic and virologic tests as screening strategies in a region at high risk of cervical cancer. Cancer Epidemiology Biomarkers and Prevention 2003;12:815-23. 5827860
61. Huang M-Z, Huang S, Li D-Q, Nie X-M, Li H-B, Jiang X-M. The study of the combination detection of HPV-DNA and p16INK4a in cervical lesions. Medical Oncology 2010;28 Suppl 1:S547-52. 5827862
62. Idelevich P, Kristt D, Schechter E, Lew S, Elkeles A, Terkieltaub D, et al. Screening for cervical neoplasia: a community-based trial comparing Pap staining, human papilloma virus testing, and the new bi-functional Cell Detect stain. Diagnostic Cytopathology 2011;40:1054-61. 5827864
63. Junyangdikul P, Tanchotsrinon W, Chansaenroj J, Nilyaimit P, Lursinsap C, Poovorawan Y. Clinical prediction based on HPV DNA testing by hybrid capture 2 (HC2) in combination with Liquid-based Cytology (LBC). Asian Pacific Journal of Cancer Prevention 2013;14:903-7. 5827866
64. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncology 2011;12:663-72. 5827868
65. Kelesidis T, Aish L, Steller MA, Aish IS, Shen J, Foukas P, et al. Human papillomavirus (HPV) detection using in situ hybridization in histologic samples: correlations with cytologic changes and polymerase chain reaction HPV detection. American Journal of Clinical Pathology 2011;136:119-27. 5827870
66. Kim JH, Kim IW, Kim YW, Park DC, Kim YW, Lee KH, et al. Comparison of single-, double- and triple-combined testing, including Pap test, HPV DNA test and cervicography, as screening methods for the detection of uterine cervical cancer. Oncology Reports 2013;29:1645-51. 5827872
67. Kitchener HC, Gilham C, Sargent A, Bailey A, Albrow R, Roberts C, et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. European Journal of Cancer 2011;47:864-71. 5827874
68. Kuhn L, Denny L, Pollack A, Lorincz A, Richart RM, Wright TC. Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. Journal of the National Cancer Institute 2000;92:818-25. 5827876
69. Li C, Wu M, Wang J, Zhang S, Zhu L, Pan J, et al. A population-based study on the risks of cervical lesion and human papillomavirus infection among women in Beijing, People's Republic of China. Cancer Epidemiology, Biomarkers & Prevention 2010;19:2655-64. 5827878
70. Li Y, Ye F, Lu W-G, Zeng W-J, Wei L-H, Xie X. Detection of human telomerase RNA gene in cervical cancer and precancerous lesions comparison with cytological and human papillomavirus DNA test findings. International Journal of Gynecological Cancer 2010;20:631-7. 5827880
71. Longatto-Filho A, Naud P, Derchain SF, Roteli-Martins C, Tatti S, Hammes LS, et al. Performance characteristics of Pap test, VIA, VILI, HR-HPV testing, cervicography, and colposcopy in diagnosis of significant cervical pathology. Virchows Archiv 2012;460:577-85. 5827882
72. Ma L, Bian M-L, Cheng J-Y, Xiao W, Hao M, Zhu J, et al. Hybrid capture II for high-risk human papillomavirus DNA testing to detect cervical precancerous lesions: a qualitative and quantitative study. Experimental and Therapeutic Medicine 2010;1:193-8. 5827884
73. Masumoto N, Fujii T, Ishikawa M, Mukai M, Saito M, Iwata T, et al. Papanicolaou tests and molecular analyses using new fluid-based specimen collection technology in 3000 Japanese women. British Journal of Cancer 2003;88:1883-8. 5827886
74. Mesher D, Szarewski A, Cadman L, Cubie H, Kitchener H, Luesley D, et al. Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study. British Journal of Cancer 2010;102:1405-10. 5827888
75. Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrjänen K, Smith JS. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study). Gynecologic Oncology 2012;125:175-80. 5827890
76. Nieminen P, Vuorma S, Viikki M, Hakama M, Anttila A. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer. BJOG 2004;111:842-8. 5827892
77. Oh YL, Shin KJ, Han J, Kim DS. Significance of high-risk human papillomavirus detection by polymerase chain reaction in primary cervical cancer screening. Cytopathology 2001;12:75-83. 5827894
78. Özcan ES, Taskin S, Ortaç F. High-risk human papilloma virus prevalence and its relation with abnormal cervical cytology among Turkish women. Journal of Obstetrics and Gynaecology 2011;31:656-8. 5827896
79. Quincy BL, Turbow DJ, Dabinett LN, Dillingham R, Monroe S. Diagnostic accuracy of self-collected human papillomavirus specimens as a primary screen for cervical cancer. Journal of Obstetrics and Gynaecology 2012;32:795-9. 5827898
80. Ratnam S, France EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiology Biomarkers and Prevention 2000;9:945-51. 5827900
81. Riethmuller D, Gay C, Bertrand X, Bettinger D, Schaal JP, Carbillet JP, et al. Genital human papillomavirus infection among women recruited for routine cervical cancer screening or for colposcopy determined by hybrid capture II and polymerase chain reaction. Diagnostic Molecular Pathology 1999;8:157-64. 5827902
82. Rijkaart DC, Berkhof J, Van Kemenade FJ, Coupe VM, Rozendaal L, Heideman DA, et al. HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications. British Journal of Cancer 2012;106:975-81. 5827904
83. Sankaranarayanan R, Thara S, Sharma A, Roy C, Shastri S, Mahé C, et al. Accuracy of conventional cytology: results from a multicentre screening study in India. Journal of Medical Screening 2004;11:77-84. 5827906
84. Sankaranarayanan R, Nene BM, Dinshaw KA, Mahe C, Jayant K, Shastri SS, et al. A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. International Journal of Cancer 2005;116:617-23. 5827908
85. Schiffman M, Herrero R, Hildesheim A, Sherman ME, Bratti M, Wacholder S, et al. HPV DNA screening in cervical cancer screening. Results from women in a high-risk province of Costa-Rica. JAMA 2000;283:87-93. 5827910
86. Shastri SS, Dinshaw K, Amin G, Goswami S, Patil S, Chinoy R, et al. Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India. Bulletin of the World Health Organization 2005;83:186-94. 5827912
87. Sherman ME, Lorincz AT, Scott D, Wacholder S, Castle PE, Glass AG, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. Journal of the National Cancer Institute 2003;95:46-52. 5827914
88. Siriaunkgul S, Settakorn J, Sukpan K, Srisomboon J, Suprasert P, Kasatpibal N, et al. Population-based cervical cancer screening using high-risk HPV DNA test and liquid-based cytology in northern Thailand. Asian Pacific Journal of Cancer Prevention 2014;15:6837-42. 5827916
89. Surabhi K, Ragini M. Complementary procedures in cervical cancer screening in low resource settings. The Journal of Obstetrics and Gynecology of India 2011;61:436-8. 5827918
90. Wang JL, Yang YZ, Dong WW, Sun J, Tao HT, Li RX, et al. Application of human papillomavirus in screening for cervical cancer and precancerous lesions. Asian Pacific Journal of Cancer Prevention 2013;14:2979-82. 5827920
91. Womack SD, Chirenje ZM, Blumenthal PD, Gaffikin L, McGrath JA, Chipato T, et al. Evaluation of a human papillomavirus assay in cervical screening in Zimbabwe. BJOG 2000;107:33-8. 5827922
92. Zhao F-H, Lin MJ, Chen F, Hu S-Y, Zhang R, Belinson JL, et al. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncology 2010;11:1160-71. 5827924
93. Anttila A, Ronco G, Clifford G, Bray F, Hakama M, Arbyn M, et al. Cervical cancer screening programmes and policies in 18 European countries. British Journal of Cancer 2004;91:935-41.
94. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J. Cytologic versus virologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. Journal of the National Cancer Institute 2004; Vol. 96:280-93.
95. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006;24 Suppl 3:78-89.
96. Arbyn M, Sankaranarayanan R, Muwonge R, Keita N, Dolo A, Mbalawa CG, et al. Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. International Journal of Cancer 2008;123:153-60.
97. Arbyn M, Raifu AO, Bray F, Weiderpass E, Anttila A. Trends of cervical cancer mortality in the member states of the European Union. European Journal of Cancer 2009;45(15):2640-8.
98. Arbyn M, Ronco G, Cuzick J, Wentzensen N, Castle PE. How to evaluate emerging technologies in cervical cancer screening?. International Journal of Cancer 2009;125:2489-96.
99. Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition--summary document. Annals of Oncology 2010;21:448-58.
100. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Annals of Oncology 2011;12:2675-86.
101. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012;30 Suppl 5:F88-99.
102. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. Journal of Clinical Pathology 2002;55:244-65.
103. Breitenecker G, Dinges HP, Regitnig P, Wiener H, Vutuc C. Cytopathology in Austria. Cytopathology 2004;15:113-8.
104. Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncology 2011;12:880-90.
105. Chan AB, Fox JD. NASBA and other transcription-based amplification methods for research and diagnostic microbiology. Review Medical Microbiology 1999;10:184-96.
106. Chu H, Cole SR. Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach. Journal of Clinical Epidemiology 2006;59(12):1331-2.
107. Dijkstra MG, Van Niekerk D, Rijkaart DC, Van Kemenade FJ, Heideman DA, Snijders PJ, et al. Primary hrHPV DNA testing in cervical cancer screening: how to manage screen-positive women? A POBASCAM trial substudy. Cancer Epidemiology, Biomarkers & Prevention 2014;23:55-63.
108. Dilner J. The serological response to papillomaviruses. Seminars in Cancer Biology 1999;9:423-30.
109. International Agency for research on Cancer. Cervix Cancer Screening: IARC Handbooks of Cancer Prevention. Vol. 10, Lyon: IARC, 2005.
110. IARC working group on the evaluation of carcinogenic risks to humans. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 90: Human Papilloma viruses. Lyon, France: IARC Press, 2007.
111. Jeronimo J, Schiffman M. Colposcopy at a crossroads. American Journal of Obstetrics and Gynecology 2006;195:349-53.
112. Jordan J, Arbyn M, Martin-Hirsch P, Schenck U, Baldauf JJ, Da Silva D, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. Cytopathology 2008;19:342-54.
113. Kjaer S. Long term predictive value of HPV testing (the Danish prospective cohort study). 21st International Human Papillomavirus Conference. Mexico City, Feb 20-26, 2004:Abstract 339.
114. Laara E, Day NE, Hakarna M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1987;1:1247-9.
115. Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang YT, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002;287:2372-81.
116. McCaffery K, Waller J, Forrest S, Cadman L, Szarewski A, Wardle J. Testing positive for human papillomavirus in routine cervical screening: examination of psychosocial impact. BJOG 2004;111:1437-43.
117. McCredie MR, Sharples KJ, Paul C, Baranyai J, Medley G, Jones RW, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncology 2008;9:425-34.
118. McIndoe WA, McLean MR, Jones RW, Mullins PR. The invasive potential of carcinoma in situ of the cervix. Obstetrics and Gynecology 1984;64:451-8.
119. Meera E, Le Gales C, Cochand-Priollet B, Cartier I, de Cremoux P, Vacher-Lavenu MC, et al. Cost of screening for cancerous and precancerous lesions of the cervix. Diagnostic Cytopathology 2002;27:251-7.
120. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLoS Medicine 2009;6(7):e1000097. [DOI: 10.1371/journal.pmed1000097]
121. Luesley D, Leeson S. NHSCSP Publication No. 20. Colposcopy and Programme Management. Guidelines for the NHS Cervical Screening Programme. Sheffield: NHS Cancer Screening Programmes, 2004.
122. Papanicolaou GN, Trauat HF. The diagnostic value of vaginal smears in carcinoma of the uterus. American Journal of Obstetrics and Gynecology 1941;42:193-206.
123. Poljak M, Cuzick J, Kocjan BJ, Iftner T, Dillner J, Arbyn M. Nucleic acid tests for the detection of alpha human papillomaviruses. Vaccine 2012;30(Suppl 5):F100-6.
124. Quinn M, Babb P, Jones J, Allen E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 1999;318:904-8.
125. Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. Journal of Clinical Epidemiology 2005;58(10):982-90.
126. Reitsma JB, Rutjes AWS, Whiting P, Vlassov VV, Leeflang MMG, Deeks JJ. Chapter 9: Assessing methodological quality. In: Deeks JJ, Bossuyt PM, Gatsonis C (editors), Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0.0. The Cochrane Collaboration, 2009. Available from: srdta.cochrane.org/.
127. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
128. Rijkaart DC, Berkhof J, Van Kemenade FJ, Coupe VM, Hesselink AT, Rozendaal L, Heideman DA, Verheijen RH, Bulk S, Verweij WM, Snijders PJ, Meijer CJ. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 2012;130:602-10.
129. Ronco G, Dillner J, Elfström KM, Tunesi S, Snijders PJ, Arbyn M, Kitchener H, Segnan N, Gilham C, Giorgi-Rossi P, Berkhof J, Peto J, Meijer CJ, International HPV sc. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383:524-32.
130. SAS Institute Inc. SAS Institute Inc. SAS/ACCESS® 9.4 Interface to ADABAS. Reference. Cary, NC, 2013.
131. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, Garcia FA, Moriarty AT, Waxman AG, Wilbur DC, Wentzensen N, Downs LS Jr, Spitzer M, Moscicki AB, Franco EL, Stoler MH, Schiffman M, Castle PE, Myers ER, American Cancer Society, American Society for Colposcopy and Cervical Pathology, American Society for Clinical Pathology. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137:516-42.
132. Schatzkin A, Connor RJ, Taylor PR, Bunnag B. Comparing new and old screening tests when a reference procedure cannot be performed on all screenees. Example of automated cytometry for early detection of cervical cancer. American Journal of Epidemiology 1897;125:672-8.
133. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370:890-907.
134. Sigurdsson K. The Icelandic and Nordic cervical screening programs: trends in incidence and mortality rates through1995. Acta Obstetricia et Gynecologica Scandinavica 1999;78:478-85.
135. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9.
136. Spence AR, Goggin P, Franco EL. Process of care failures in invasive cervical cancers: A systematic review and meta-analysis. Preventive Medicine 2007;45:93-106.
137. StataCorp. StataCorp. Stata Statistical Software: Release 14. College Station, TX. StataCorp LP, 2015.
138. Stoler MH, Schiffman M. Atypical squamous cells of undetermined significance-low grade squamous intraepithelial lesion triage study (ALTS) group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL triage study. JAMA 2001;285:1500-5.
139. Twakoingi Y, Deeks JJ. MetaDAS: A SAS macro for meta-analysis of diagnostic accuracy studies. Quick reference and worked example. Available from methods.cochrane.org/sdt/software-meta-analysis-dta-studies. 1.3 2010.
140. Walboomers JMM, Jacobs MV, Manos MM, Bosch X, Kummer A, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Journal of Pathology 1999;189:12-9.
141. Wentzensen N, Walker JL, Gold MA, Smith KM, Zuna RE, Mathews C, et al. Multiple biopsies and detection of cervical cancer precursors at colposcopy. Journal of Clinical Oncology 2015;33:83-9.
142. Whiting P, Rutjes AWS, Reitsma JB, Bossuyt PMM, Kleijnen J. The development of QUADAS: A tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Medical Research Methodology 2003;3:25.
143. Wilson JMG, Jungner G. Principles and practice of screening for disease. Public Health Papers. Vol. 34, Geneva: World Health Organization, 1968.
144. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. American Journal of Obstetrics and Gynecology 2007;197:346-55.